PTG-300 Hepcidin Mimetic Receives FDA Orphan Drug Designation for Treatment of Polycythemia Vera

NEWARK, Calif., June 17, 2020 /PRNewswire/ — Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for PTG-300 for the treatment of polycythemia vera. PTG-300 is an injectable synthetic peptide mimetic of the natural hormone hepcidin currently in clinical development for the treatment of polycythemia vera and hereditary hemochromatosis. “Receiving […]

MPN Specialist Explains PTG-300 and Clinical Trial for PV Patients

by David Wallace Hepcidin Mimetic PTG-300 Promising Treatment for PV How does PTG-300 work to reduce or eliminate the need for phlebotomy in PV?  How does iron deficiency play a role in polycythemia vera?  What are the goals of this treatment?  Leading MPN expert, Dr. Srdan Verstovsek, from MD Anderson Cancer Center, interviews with David […]

Ropeginterferon Effective Treatment for Polycythemia Vera

Thrombotic Risk Reduction and High Rate of Complete Molecular Response with the Long Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera:  Results from a Randomized Controlled Study, ASH 2019 interview with Dr. Kiladjian by David Wallace Dr. Jean Jacques Kiladjian, Professor of Clinical Hematology, Hopital Saint-Louis, Paris, France interviews with David Wallace, PV Reporter at […]

Dr. Jean Jacques Kiladjian ASH 2018 RuxoPeg Phase 1/2 Trial of the Combo of Ruxolitinib and Pegasys in Myelofibrosis Patients

RUXOPEG is the first study to formally assess the safety and efficacy of Rux + IFNa combination in MF patients never exposed to either drugs before First in ASH 2018 Series by David Wallace Dr Jean Jacques Kiladjian, Professor of Clinical Hematology, Hopital Saint-Louis, Paris, France interviews with David Wallace, PV Reporter at ASH 2018.  […]

Incyte conducts Phase 2 Clinical Trials for Myelofibrosis and Essential Thrombocythemia

Myelofibrosis A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis The purpose of this study is to evaluate the safety, tolerability, and efficacy of the combination of INCB050465 and ruxolitinib in subjects with myelofibrosis Talk to your doctor if you are interested in participating […]

MPN Clinical Trial updates from Geron and Promedior

Geron announces removal of Full Clinical Hold on Imetelstat The full clinical hold on Geron’s sole pipeline candidate, investigation new drug (IND), Imetelstat, has been lifted by the FDA.  The company does not intend to conduct further studies or develop imetelstat for the treatment of essential thrombocythemia (ET) or polycythemia vera (PV).  The development plan […]

Imetelstat Trials for MF moves forward as FDA removes hold

Geron Corp announced today that the partial clinical hold on clinical trials of imetelstat in myelofibrosis has been removed by the FDA. The hold for essential thrombocythemia and polycythemia vera remains. Click here for the full story.

error: Content is protected !